You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 7, 2025

Details for Patent: 9,283,238


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,283,238 protect, and when does it expire?

Patent 9,283,238 protects TAVALISSE and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: 9,283,238
Title:Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Inventor(s): Bhamidipati; Somasekhar (Foster City, CA), Singh; Rajinder (Belmont, CA), Sun; Thomas (Palo Alto, CA), Masuda; Esteban (Menlo Park, CA)
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:14/534,784
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of a US Patent: A Detailed Analysis

Introduction

When navigating the complex world of intellectual property, understanding the scope and claims of a US patent is crucial for inventors, businesses, and legal professionals. This article delves into the intricacies of patent claims, the patent landscape, and the processes involved in obtaining and maintaining a US patent, using the example of US Patent 9,283,238.

What is a US Patent?

A US patent is a grant of exclusive rights to an inventor for their invention, issued by the United States Patent and Trademark Office (USPTO). This grant is made in exchange for the public disclosure of the invention.

The Patent Application Process

To obtain a US patent, an inventor must file a patent application with the USPTO. This process involves several key steps:

Filing the Application

The application includes a detailed description of the invention, drawings, and claims that define the scope of the invention[1].

Examination

The USPTO examines the application to determine if the invention meets the criteria for patentability, including novelty, non-obviousness, and utility. This process can take several years, with the average time to first Office action being around 15 months and the total pendency time often exceeding four to five years[1].

Allowance or Abandonment

If the application meets the criteria, it is allowed and a patent is granted. However, if it does not meet the criteria, the application may be abandoned. According to a study, only 55.8% of patent applications filed between 1996 and 2013 were eventually granted without using continuation procedures[1].

Patent Claims

Definition and Importance

Patent claims are the legal definitions of the invention and define the scope of protection granted by the patent. They are the most critical part of the patent application, as they determine what is protected and what is not.

Types of Claims

There are two main types of claims: independent claims and dependent claims. Independent claims stand alone and define the invention without reference to other claims. Dependent claims, on the other hand, refer back to and further limit an independent claim[3].

Example: US Patent 9,283,238

US Patent 9,283,238, titled "Methods and Compositions for Treating Immune Thrombocytopenia," is an example of a patent with detailed claims. This patent, assigned to Rigel Pharmaceuticals, Inc., includes claims related to methods of treating immune thrombocytopenia using fostamatinib disodium hexahydrate. The claims specify the dosage, administration, and patient populations, thereby defining the scope of the invention[5].

Patent Scope and Landscape

Patent Scope Measurements

The USPTO has developed measures to quantify patent scope, including the number of claims, claim length, and dependency relationships between claims. These measures help in understanding the breadth and depth of the patent protection[3].

Technology Fields

Patents are categorized into various technology fields, such as Chemical, Drugs and Medical, Electrical and Electronics, and Computers and Communications. The allowance rate and patent scope can vary significantly across these fields. For instance, the allowance rate has decreased substantially over time, particularly in the “Drugs and Medical Instruments” and “Computers and Communications” fields[1].

Quality and Correctness of Patents

USPTO's Quality Initiatives

The USPTO has implemented various measures to ensure the quality of patents. This includes defining patent quality, articulating this definition in agency documents, and setting quantifiable compliance targets. For example, the USPTO calculates statutory compliance rates for different sections of the patent law (35 U.S.C. 101, 112, 102, and 103) to ensure that patents meet the required standards[4].

Challenges and Considerations

Small Claims Patent Court

There have been discussions and studies on the feasibility of a small claims patent court to address the high costs and complexities associated with patent litigation. The Administrative Conference of the United States (ACUS) conducted a study on this topic, engaging with various stakeholders to understand the need, structure, and legal considerations for such a court[2].

Time and Resources

The examination process requires significant time and resources. The USPTO has increased the time available for certain art units to ensure thorough examinations, reflecting the complexity and the need for detailed analysis in certain technology areas[4].

Key Takeaways

  • Patent Claims: The heart of a patent application, defining the scope of protection.
  • Patent Scope: Measured through various metrics, including claim count and dependency relationships.
  • Technology Fields: Allowance rates and patent scope vary across different fields.
  • Quality Initiatives: USPTO's efforts to ensure patent quality through compliance targets and statutory compliance rates.
  • Challenges: High costs of litigation and the need for thorough examinations.

FAQs

What is the average allowance rate for US patent applications?

The average allowance rate for US patent applications is approximately 55.8% without using continuation procedures[1].

How long does the patent examination process typically take?

The patent examination process can take around four to five years from the filing date to the final examination outcome[1].

What are the main types of patent claims?

The main types of patent claims are independent claims and dependent claims[3].

Why is patent quality important?

Patent quality is crucial to ensure that patents meet the required standards of novelty, non-obviousness, and utility, and to maintain the integrity of the patent system[4].

Is there a proposal for a small claims patent court?

Yes, there have been studies and discussions on the feasibility of a small claims patent court to address the high costs and complexities of patent litigation[2].

Sources

  1. Carley, M., Hegde, D., & Marco, A. (2015). What Is the Probability of Receiving a US Patent? Yale Journal of Law & Technology, 17, 203.
  2. Administrative Conference of the United States. (2022). U.S. Patent Small Claims Court.
  3. USPTO. (2017). Patent Claims Research Dataset.
  4. GAO. (2016). Intellectual Property: Patent Office Should Define Quality, Reassess Compliance Targets.
  5. Rigel Pharmaceuticals, Inc. (n.d.). Patent Notice.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,283,238

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rigel Pharms TAVALISSE fostamatinib disodium TABLET;ORAL 209299-001 Apr 17, 2018 RX Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT ⤷  Subscribe
Rigel Pharms TAVALISSE fostamatinib disodium TABLET;ORAL 209299-002 Apr 17, 2018 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.